

# Practical Approach to Desmoid Tumours

October 22, 2011

Lloyd Mack Surgical Oncology University of Calgary





 To appreciate the evolving treatment of desmoid tumours – from surgical disease to multidisciplinary condition

 To describe a surgical approach to desmoid tumours based on their biologic aggressiveness



#### Classification of Soft Tissue Tumors

 Locally recurring ST neoplasm with little or no metastatic potential

- Sarcomas with metastatic potential of LESSER aggressiveness
- Aggressive Sarcomas



Locally Recurring Soft Tissue Neoplasms with Little or No Metastatic Potential

Desmoid Tumour

- Atypical Lipomatous Tumour
  - Low grade liposarcoma

Dermatofibrosarcoma proturberans
 (DFSP)



#### Definition

- Synonyms musculoaponeurotic fibromatosis, deep fibromatosis, aggressive fibromatosis, desmoid tumor, well-differentiated nonmetastasizing fibrosarcoma, grade I fibrosarcoma
- Locally aggressive, histologically benign neoplasms with unpredictable growth, invasion, and symptoms including pain, deformity, dysfunction, and possible death
- No metastatic potential; do not de-differentiate

Weiss and Goldblum Soft Tissue Tumors 2001 Lewis et al Ann Surg 1999;229:866-73 Schajowicz et al Cancer 1995;75:1208-14



#### **Presentation**

- Incidence 2-4/ million/ yr
- Present as a mass in general locations
  - Intra-abdominal/ Mesenteric (5-10%)
  - Abdominal wall (20%)
  - Extra-abdominal limb, chest, breast, neck (65-70%)
- Young adults, peak incidence 30 years, 2/3:1/3 female:male gender distribution, majority are solitary (5% multicentric), majority are sporadic (95-98%)

Ballo et al J Clin Oncol 1999;17:158-67 Gronchi et al J Clin Oncol 2003;21:1390-7





- Unclear
- Trauma, especially surgical trauma
- Hormonal 2/3 female, may grow during pregnancy
- Genetic Familial Adenomatous Polyposis
  - Aka Gardner's syndrome
  - 1/5 patients with FAP will develop desmoid tumours
  - 1000 x greater than population
  - ≈2 years after surgery; median age 30; usually intra-abdominal

Groen et al Ann Surg Oncol 2008;15:2439-50



#### **Evaluation**

- History: lump or swelling
  - ?growth plateau, ?regression
  - location specific symptoms

#### Physical Examination

- size, superficial vs. deep
- neurovascular evaluation, deficits
- Investigations
  - plain radiographs, U/s to confirm mass
  - CT or MRI to define location, margins, relation, heterogeneity

Guglielmi et al Radiol Med 2009;114:1292-1307



# **Biopsy Approach**

- Image directed core biopsy
  - Multiple samples sufficient to make diagnosis in 90% of STS
- Incisional biopsy
  - Same principles as STS
- Excisional biopsy
  - Unusual since deep
- Review by expert soft tissue pathologist
  - Well-differentiated intertwining fibroblasts in bundles with abundant collagen matrix

Welker et al Cancer 2000;39:2677-86 Hoeber et al Ann Surg Oncol 2001;8:80-7



### Surgical Principles

- Treatment should be tailored consider multidisciplinary input up front
- Ideal surgical resection with wide (1-2 cm) gross margin/ pathologically clear margins
- Many caveats
  - Surgical resection may not be possible/ feasible
  - Surgical resection may not be possible with negative margins without major disability
  - Role of microscopic margins not clear cut





#### When is a Neoplasm not a Neoplasm? When it is a Desmoid

DOUGLAS B. ZIPPEL, MD\* AND WALLEY J. TEMPLE, MD Division of Surgical Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada

#### The Enigma of Desmoid Tumors

Jonathan J. Lewis, MD, PhD,\* Patrick J. Boland, MD,\* Dennis H. Y. Leung, PhD,† James M. Woodruff, MD,‡ and Murray F. Brennan, MD\*

From the Departments of \*Surgery, †Biostatistics, and ‡Pathology, Memorial Sloan-Kettering Cancer Center, New New York

#### Optimizing Treatment of Desmoid Tumors

Dina Lev, Dhanasekaran Kotilingam, Caimiao Wei, Matthew T. Ballo, Gunar K. Zagars, Peter W.T. Pisters, Alexander A. Lazar, Shreyaskumar R. Patel, Robert S. Benjamin, and Raphael E. Pollock

#### INDIVIDUALIZING MANAGEMENT OF AGGRESSIVE FIBROMATOSES

MATTHEW A. SPEAR, M.D.,\* L. CANDACE JENNINGS, M.D.,<sup>†</sup> HENRY J. MANKIN, M.D.,<sup>†</sup> IRA J. SPIRO, M.D., PH.D.,\* DEMPSY S. SPRINGFIELD, M.D.,<sup>†</sup> MARK C. GEBHARDT, M.D.,<sup>†</sup> ANDREW E. ROSENBERG, M.D.,<sup>‡</sup> JAMES T. EFIRD, PH.D.,\* AND HERMAN D. SUIT, M.D.\*

Departments of \*Radiation Oncology, <sup>†</sup>Orthopaedic Surgery and <sup>‡</sup>Pathology, Massachusetts General Hospital, Harvard University Medical School, Boston, MA 02114

#### Desmoid-Type Fibromatosis: A Front-Line Conservative Approach to Select Patients for Surgical Treatment

Marco Fiore, MD<sup>1</sup>, Françoise Rimareix, MD<sup>2</sup>, Luigi Mariani, MD<sup>3</sup>, Julien Domont, MD<sup>4</sup>, Paola Collini, MD<sup>5</sup>, Cecile Le Péchoux, MD<sup>6</sup>, Paolo G. Casali, MD<sup>7</sup>, Axel Le Cesne, MD<sup>4</sup>, Alessandro Gronchi, MD<sup>1</sup>, and Sylvie Bonvalot, MD, PhD<sup>2</sup>

<sup>1</sup>Department of Surgery, Istituto Nazionale Tumori, Milan, Italy; <sup>2</sup>Department of Surgery, Institut Gustave Roussy, Villejuif, France; <sup>3</sup>Department of Biostatistics, Istituto Nazionale Tumori, Milan, Italy; <sup>4</sup>Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France; <sup>5</sup>Department of Pathology, Istituto Nazionale Tumori, Milan, Italy; <sup>6</sup>Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France; <sup>7</sup>Department of Cancer Medicine, Istituto Nazionale Tumori, Milan, Italy



## **Biology...?**

- Well described variation in growth
  - 50% have period of stability
  - 30% cycles of progression / stability
  - 10% rapidly progress
  - 10% regress/ resolve
- Key study 198 pts, 68 pts with recurrent desmoid tumours were followed
  - Median f/u 6 yrs; 60 stable, 6 regressed
  - Stability of lesion considered a 'success'

Church JM Semin Colon Rectal Surg 1995;6:29-32 Rock et al J Bone Joint Surg Am 1984;66:1369-74





- MD Anderson comparison of 189 pts from 1965-94 with 189 pts from 1995-2005
- Trends in 2<sup>nd</sup> compared to 1<sup>st</sup> time period
  - Increased multimodal therapy
  - Less reliance on surgery alone
  - Higher rates of macroscopic residual disease and equivalent positive margins
  - 5 yr local recurrence 20% vs. 30%
  - More patients had radiation alone (9) or systemic treatment alone (29) – all have remained alive with at least stable disease
  - A subset refused treatment

Lev et al J Clin Oncol 2007;25:1785-91



#### **Observation?**

- Milan Series since 2003, all patients initially recommended a conservative approach (nonoperative; no RT)
- 142 pts (74 primary, 68 recurrent)
   -83 pts had wait and see approach (W&S)
   -59 pts offered medical therapy (MT)
- 5 year PFS 49.9% (W&S), 58.9% (MT)
- Multivariate analysis did not identify predictors of stability or regression
- Overall, 1/2 avoided any treatment; 2/3 of pts avoided surgery
   Fiore et al Ann Surg Oncol 2009;16:2587-93



#### Summary

- **Paradigm shift** from a 'cancer' paradigm to a 'chronic' condition
- Stability may be a success
- Period of observation warranted
- Role of alternate agents and primary irradiation underappreciated
- Surgery still has a major role

Zippel, Temple J Surg Oncol 2007;95:190-1




- Ideally treatment should be tailored consider multidisciplinary input up front
- Ideal surgical resection with wide (1-2 cm) gross margin/ pathologically clear margins
- Many caveats
  - Surgical resection may not be possible/ feasible
  - Surgical resection may not be possible with negative margins without major disability
  - Role of microscopic margins not clear cut
- Need to start somewhere.....



 Consider resection alone when feasible (i.e. easy)

46 y.o. female4 month hx of painlessmass2.5x1.5cm





### Local Recurrence/ Surgery Alone

- Review 22 series, 381 pts 1983-99
   61% overall local control rate 72% m-; 42% m+
- Review 12 series, 412 pts 1969-2003 45% overall local control rate

Series	Patients (#)	Local Control (5 yr) (%)
MD Anderson	122	66
Milan	198	73
MSKCC	158	77

Nuyttens et al Cancer 2000;88:1517-23 Leithner et al J Surg Oncol 2004;86:152-6 Ballo et al J Clin Oncol 1999;17:158-67 Gronchi et al J Clin Oncol 2003;21:1390-7 Merchant et al Cancer 1999;86:2045-52



## Margins?

- Outcomes influenced by location, proximity to vital organs, and association with FAP
- Significance of positive margins review of 23 studies
  - Most older studies suggest higher LR with microscopically positive margins; Larger more recent publications have challenged this assumption
  - Local recurrence itself doesn't predict uncontrolled tumor growth
- Options may include re-resection, adjuvant radiation or close follow-up
- If a desmoid has 'stopped' growing, margin status becomes less critical, especially if function / QoL may compromised
   Melis et al J Surg Oncol 2008;98:594-602



#### Prognostic Features


- ? Prior recurrence predicts worse outcome
- ? Age (<=30 yrs worse than >30)
- ? Surgery alone worse than combined therapy
- ? Size >5cm >8 cm
- ? Difficult sites intra-abdominal vs. extraabdominal or abdominal wall
  - Calf, foot, supraclavicular fossa, popliteal fossa, buttock

Ballo et al J Clin Oncol 1999;17:158-67 Nuyttens et al Cancer 2000;88:1517-23 Catton et al Radiother Oncol 1995;34:17-22



 Consider alternate modalities if not feasible or too disabling

16 y.o. female
2 year hx of slowly
growing mass
15x5x3cm; on sciatic
nerve





#### Consider alternate modalities if not feasible or too disabling

18 y.o. male U/s screen for polycystic kidneys Large pelvic mass 11.7x11x9.4cm





#### Consider alternate modalities if not feasible or too disabling

52 y.o. female Presented with anemia and abdominal mass Root of mesentery encasing sma/smv





#### **Alternate Therapy**

- Alternate therapies include:
  - Anti-inflammatories, tamoxifen, irradiation as primary treatment, cytotoxic chemotherapy....





# **Alternate Therapy**


- Tamoxifen/ anti-inflammatories
  - 20-30% overall response rate but stable in 40-50%
  - Sulindac 10-30% often in combination
- Cytotoxic chemotherapy
  - 68 patients median age 32; 2/3 female; 53% had an intraabdominal tumor; 1/3 had Gardner's; range of surgeries (1-5)
  - 50% had tumors >10 cm; 5 were multifocal
  - Median of 2 lines of chemotherapy (1-7)
  - Best responses with anthracycline agents (35-60%)
  - Vinblastine/ MTX 30-40%; Imatinib 5-16%
  - Overall 21% partial response and 15% progressed
  - Progression-free survival 12 months
  - Median survival 13 years (FAP); 90% 10-20 year sporadic



## **Surgical Adjuncts?**

- Surgical Adjuncts?
  - Insertion of spacer to facilitate irradiation
  - Bypass surgery, control of perforation






#### White et al Ann Surg Oncol 2007;14:583-90




 Is there an operation? Is it possible to get 'good' margins?

60 y.o. female with progressive, painful mass
7x6.8x2.3 cm involving 6-8th ribs





- Is there an operation? YES
- Is it possible to get 'good' margins? Difficult
- Patient had preoperative chemoradiation, wide resection including chest wall, reconstruction with alloderm, latissimus flap





#### Francis et al Ann Surg Oncol 2009:16:1650-4



 Is there an operation? Is it possible to get 'good' margins?

43 y.o. female with initially asymptomatic RLQ mass
7.7x5.1x5.8 cm mass in mesentery
Right hydroureter; intimate with iliac vessels





- Is there an operation? Yes
- Is it possible to get 'good' margins? Unlikely
- Patient had preoperative irradiation (50 Gy) with use of spacer
- Surgery included Rt colectomy, Rt nephrectomy, Iliac vessel resection/ replacement



McKay et al J Surg Oncol 2007;96:151-9



#### Surgery as part of Multimodal Treatment

- Review 22 series, 381 pts 1983-99
- Surgery alone 61% local control (72m-;41m+)
- Surgery + radiation 75% (94m-;75m+)
- Primary radiation 78%

Series	Patients	Local Control
	(#)	(5 yr) (%)
MD Anderson	75	78
UCLA	56	78
U of Florida	72	83

Nuyttens et al Cancer 2000;88:1517-23Ballo et al Int J Rad Oncol Biol Phys 1998Goy et al Int J Rad Oncol Biol Phys 1997Zlotecki et al Int J Rad Oncol Biol Phys 2003



#### Surgery as part of Multimodal Treatment

- Comments differing definitions of local control for primary surgery and primary irradiation; in general patients receiving adjuvant radiation were worse
- Preoperative Radiation

   less commonly used 7 pt series

Ballo et al J Clin Oncol 1999;17:158-167



### Surgery as part of Multimodal Treatment

- Cancer Centre Review- 52 patients 1990-2008
- 52 patients (40 female, 12 male) 45 month f/u
- Overall 39 had surgery; 13 non-operative
- Tamoxifen/ NSAID (all after 2001)-
  - 16 pts 6 stable, 1 PR, 1 CR, 6 progressed -50% success
- 9 surgery alone 78% (7/9) control
- Preoperative Chemoradiation and Surgery -30 patients– 90% local control rate

Francis et al Ann Surg Oncol 2009;16:1650-54



### **Algorithm/ Conclusion**

- Trial of observation should be standard to determine the underlying growth pattern/ biology
- Hormonal therapy and anti-inflammatories may be considered early with stabilization considered a success



## **Algorithm/ Conclusion**

- Beyond this, surgery is a key component of the multidisciplinary care of desmoid tumours
  - Surgery alone when feasible (...easy, although rare)
  - Avoid surgery or use surgery in a supportive fashion (i.e. facilitate RT) when not feasible or will result in major disability or disfigurement
  - As a component of multimodal treatment (reserve most aggressive treatment for more aggressive biology)



#### **Questions?**

